Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | ADK | P55263 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903071 | 0.77 | NISCH (0.42) | PDE3BPDE3ANISCHMTORADK | |
| SCHEMBL197279 | 0.75 | NISCH (0.54) | PDE3BPDE3ANISCHMTORADK | |
| SCHEMBL18210595 | 0.74 | AXL (0.44) | ALDH1A1KDM4EKMT2AAXLNUDT1 | |
| SCHEMBL20595280 | 0.72 | NISCH (0.45) | PDE3BPDE3ANISCHMTORADK | |
| SCHEMBL1194064 | 0.72 | KDM4E (0.55) | ALDH1A1KDM4EAXLNUDT1CYP1A2 | |
| SCHEMBL7210200 | 0.71 | MAPK1 (0.50) | IDO1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL916878 | 0.70 | CCNT1 (0.48) | CYP3A4 | |
| SCHEMBL18210602 | 0.70 | MAPK1 (0.40) | NISCHAXLNUDT1CYP3A4 | |
| SCHEMBL10986982 | 0.70 | — | — | |
| SCHEMBL5491437 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119320393-A | Bicyclo [5,6] imidazole pyrimidinone derivative, preparation method and application thereof | 上海枢境生物科技有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-119320393-A | Bicyclo [5,6] imidazole pyrimidinone derivative, preparation method and application thereof | 上海枢境生物科技有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-118221687-B | Bicyclo [5,6] imidazole pyrimidinone derivative, preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-118221687-B | Bicyclo [5,6] imidazole pyrimidinone derivative, preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-118221687-A | Bicyclo [5,6] imidazole pyrimidinone derivative, preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118221687-A | Bicyclo [5,6] imidazole pyrimidinone derivative, preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-113604148-B | Nano SiO2Modified quadruple hydrogen bond type self-repairing polyurethane coating and preparation method thereof | 深圳市博仲实业有限公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-3291817-B1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10195201-B2 | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180280390-A1 | Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-04 | — | — | US | disclosed |
| EP-3291817-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016179059-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | WO | disclosed |
| WO-2005061505-A1 | BICYCLIC IMIDAZOLYL PYRIMIDIN-4-ONE CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280390-A1 | Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors | PDE2A, PDE12, PDE7B | PDE3B 7/4885PDE3A 6/4885NISCH 2247/4885 |
| US-10195201-B2 | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE7B | PDE3B 7/4885PDE3A 6/4885NISCH 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.